Viral receptor trap and viral myocarditis

LI Fen

DOI: https://doi.org/10.3969/j.issn.1000-3606.2007.10.001

2007-01-01

Abstract:Coxsackievirus B(CVB)is the most common pathogen that causes human viral myocarditis. CVB predominantly interacts with two receptors,the coxsackievirus and adenovirus receptor(CAR)and the decay-accelerating factor(DAF/CD55), for the attachment at myocardial cell surface and the subsequent internalization. In recent years,virus receptor trap has been used to neutralize CVB3 in experimental murine viral myocarditis and has demonstrated good antiviral effects. The so-called"virus receptor trap therapy"refers to the use of synthetic soluble virus receptor to bind to virus and thereby blocks the binding of virus to the target cell membrane receptors and the subsequent interna-lization. The virus receptor trap therapy deepens the understanding of the pathogenesis of viral myocarditis,expands the treatment strategy and may be used as a potential candidate for a novel therapeutic agent for the treatment of acute viral myocarditis.